Phase 2 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were male or female at birth, including all gender identities
- People who are 18 years of age or older at the time of signing the consent form
- People with a Body Mass Index (BMI) of 30 or higher at the screening appointment (BMI is a number calculated from height and weight)
- People who want to lose at least 25% of their body weight and are committed to that goal from the start of the trial
Who may not be able to join:
- People with a known or suspected allergy or sensitivity to the study treatment or similar products
- People who have taken any prescribed medication for obesity or weight management in the 90 days before screening — this includes medications known as GLP-1 receptor agonists (such as some injectable weight loss drugs), dual GLP-1/GIP receptor agonists, or amylin analogues
- People whose blood sugar control measurement (called HbA1c, a test that reflects average blood sugar levels over time) is 6.5% or higher at the screening appointment
- People with a history of type 1 or type 2 diabetes
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of gastrointestinal adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.